Your doctor should conduct regular monitoring during Zepbound treatment, including weight and vital signs at each visit, periodic assessment of obesity-related conditions, monitoring for adverse effects (including potential pancreatitis, gallbladder disease, dehydration, or allergic reactions), and laboratory testing as indicated (such as hemoglobin A1c if you have diabetes)
Many people achieve significant results with very few side effects because their bodies adapt efficiently to the hormone signals
Zepbound is an injectable prescription drug that the US Food and Drug Administration (FDA) approved in 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol)
With the exception of a higher risk of migraine compared to glipizide, semaglutide showed no increased risk for psychiatric or neurological outcomes
[12] [1] If pancreatitis is suspected (persistent, severe abdominal pain), Rybelsus should be discontinued immediately and urgent medical assessment sought
